AI & Antibodies miniseries
In this episode, the fifth in our miniseries covering the mAbs journal article collection on artificial intelligence and machine learning in antibody development, we speak to Aubin Ramon…
Read the full articleYou might also wanna read
AI-Driven Protein Binder Design: Progress and Pitfalls in Evaluation Practices
Build better molecules with frontier AI models. With AI, we help every scientist reshape biology.
boltz.bio·18d ago
The future of computational biology for macromolecules in the age of AI: challenges and opportunities
We have seen more progress in computational biology for macromolecules in the last five years than we experienced in the five preceding deca
journals.plos.org·8d agoThe future of computational biology for macromolecules in the age of AI: challenges and opportunities
We have seen more progress in computational biology for macromolecules in the last five years than we experienced in the five preceding deca
journals.plos.org·8d ago
Reflections on 2024 Bio-ML Predictions: Generative Chemistry and Molecular Dynamics Challenges
6.6k words, 30 minutes reading time
owlposting.com·6mo agoHow AI Is Accelerating Recombinant Protein Engineering
Predictive modeling platforms are helping scientists design more stable, scalable proteins for biomanufacturing and therapeutic research.
AI Drug Discovery Stalled by Lack of Trustworthy Biological Data
To unleash the potential of AI in life sciences and drug discovery, biological datasets must be authenticated, validated, and supported by s
The Scientist·24d agoAI Drug Discovery Stalled by Lack of Trustworthy Biological Data
To unleash the potential of AI in life sciences and drug discovery, biological datasets must be authenticated, validated, and supported by s
the-scientist.com·24d ago
Benchmarking Codon Optimization Strategies for Improved Antibody Expression
Webinar Codon Optimization Isn’t Equal: Benchmarking Gene Design for Antibody Expression On-demand Webinar Watch the Webinar Key takeaways i
hubs.li·21d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.